Get Access to Cobimetinib in India

Cobimetinib is an oral medication that falls under the category of targeted therapies. It is a MEK kinase inhibitor, recommended in the treatment of unresectable or metastatic melanoma. Going by the FDA approval, the specific indications are in the patients with BRAF V600E or V600K mutation. Wild-type BRAF melanoma patients cannot be given Cobimetinib. This drug is developed by the companies very well known names in the arena of Oncology drug innovation - Exelixis and Genentech. Cobimetinib in India can be sourced through legal import channels.

Being an oral option of medication which is also given in another oral combination namely vemurafenib, this drug is a convenient treatment option. Cotellic in India is often enquired by Oncologists treating Melanoma. Cotellic is the brand name for Cobimetinib which has global presence. Considering the data and promising outcomes, Indian consultants often recommend advanced drugs to enhance the treatment planning and outcomes. FDA approval was granted to this drug for the first time in 2014. This was under the orphan drug status. With the treatment options swiftly moving towards Immunotherapy, there is more scope for targeted therapies.

Cotellic in India is also prescribed based on the global guidelines. It is given along with vemurafenib for 21 days in a 28 days cycle. Cotellic 20mg tablets are available in a pack of 63 tablets. Promoted by Genentech as per the packaging information, one pack of 63 tablets could be used for a month if the dosage is 60mg per day.